

Q1 2026 *Results*



- We had a strong start to 2026 with double-digit sales and business EPS growth in the first quarter. We delivered important milestones for patients with five regulatory approvals, all in immunology, one positive phase 3 study readout in rare diseases, and encouraging phase 2 data in respiratory diseases. •

Olivier Charmeil

Interim Chief Executive Officer, Sanofi

Q1 2026 company sales

€10.5bn

+13.6% at constant exchange rates
+6.2% on a reported basis

Q1 2026 business earnings per share

€1.88

+14.0% at constant exchange rates
+5.0% on a reported basis

Sales by category



Dupixent

€4.2bn



Pharma launches

€1.2bn



Vaccines

€1.3bn



Other medicines

€3.9bn

sanofi

Q1 2026 *Results*

Sales by geography

US
€5.3bn

Europe
€2.2bn

Rest of the World
€3.1bn

Pipeline progress

- **5** regulatory approvals, all in immunology
 - **2** positive pipeline readouts in rare diseases and respiratory diseases
 - **2** regulatory submission acceptances in the US and Europe
-

For further information on Q1 2026 results and definitions of financial indicators, please refer to the press release issued on April 23, 2026 at: www.sanofi.com/en/investors